Cancer News and Research

Latest Cancer News and Research

Virginia Hospital Center selects CredenceHealth to provide best quality of care for patients

CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that Virginia Hospital Center , a 342-bed not-for-profit hospital in Arlington, Virginia, has selected CredenceHealth for the hospital's latest patient quality improvement initiative.

7 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.

7 Jul 2010

Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis.

7 Jul 2010

Study finds additional targets for new therapies to treat advanced prostate cancer patients

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

7 Jul 2010

VA addresses health concerns including possible HIV exposure and Veterans' general poor health

"The Democratic chairman of the House Veterans Affairs Committee lambasted the Obama administration over its handling of an incident at a St. Louis VA center in which more than 1,800 veterans were told they may have been exposed to HIV. ... The Department of Veterans Affairs last month sent a letter to 1,812 patients informing them that could have been exposed to HIV and other deadly viruses because of dental equipment that was insufficiently sterilized over a period of 13 months."

7 Jul 2010

Aspire Capital Fund to purchase Bionovo shares of common stock worth $15.0 million

Bionovo, Inc. (Nasdaq: BNVI) announced today that it has entered into a common stock purchase agreement with Aspire Capital Fund LLC, an Illinois limited liability company, which provides that, subject to certain conditions and limitations, Aspire Capital is committed to purchase up to an aggregate of $15.0 million of Bionovo shares of common stock over a two year term, based on prevailing market prices over a period preceding each sale.

7 Jul 2010

Hologic enters definitive agreement to acquire Sentinelle Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that it has entered into a definitive agreement to acquire Sentinelle Medical Inc., a leading provider of Magnetic Resonance Imaging (MRI) breast coils, tables and visualization software.

From Hologic, Inc. 7 Jul 2010

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.

7 Jul 2010

Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena Cava Filter

Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.

7 Jul 2010

International conference focuses on HPV's impact on women

Scientists, clinicians and public health leaders from around the world are gathered in Montreal this week for the 26th International Papillomavirus Conference where they hope to generate awareness about human papillomavirus, Canwest News Service/Gazette reports (Martin/McCallum, 7/4).

7 Jul 2010

PI3 kinase boosts body heat, helps burn excess calories

New findings by UT Southwestern Medical Center researchers suggest that an enzyme in the brain known as PI3 kinase might control the increased generation of body heat that helps burn off excess calories after eating a high-fat meal.

7 Jul 2010

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

In their latest research, scientists of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, Germany, have demonstrated how the brain's own stem cells and precursor cells control the growth of glioblastomas. Of all brain tumors, glioblastomas are among the most common and most aggressive.

7 Jul 2010

CPRIT grants RBM $3 million Company Commercialization Award to expand OncologyMAP program

Rules-Based Medicine, Inc. (RBM) today announced the Cancer Prevention and Research Institute of Texas (CPRIT) has granted it a Company Commercialization Award to expand and enhance the OncologyMAP™ program for discovery and development of novel diagnostic and prognostic cancer tests. The award of approximately $3 million will fund research and development to more than double the number of cancer-associated biomarker assays in RBM's new OncologyMAP™ product.

6 Jul 2010

Amorfix partners with reMYND to offer A4 amyloid testing services

Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).

6 Jul 2010

Elsevier, SIOG launch Journal of Geriatric Oncology

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, and the International Society of Geriatric Oncology (SIOG) announced today the launch of the Journal of Geriatric Oncology. The journal is focused on advancing research in the pathogenesis, biology, treatment, and survivorship issues of older adults with cancer. It covers all aspects of geriatric oncology, from basic scientific research through to clinical research, as well as research that is relevant to education and policy development.

6 Jul 2010

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan.

6 Jul 2010

Hope for ovarian cancer patients not responding to conventional chemotherapy

Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovarian cancer patients who no longer respond to conventional chemotherapy.

6 Jul 2010

$CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL$

CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL

Cell Therapeutics, Inc. announced today that it has submitted an expanded Pediatric Investigation Plan to the European Medicines Agency, as part of the process for its submission for a Marketing Authorization Application for pixantrone in the E.U. for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

6 Jul 2010

Novel molecular pathway that regulates invasive growth, metastasis in ER-positive breast cancer discovered

A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.

6 Jul 2010

Cancer News and Research

Latest Cancer News and Research

Virginia Hospital Center selects CredenceHealth to provide best quality of care for patients

QIAGEN receives CE conformity marking for careHPV Test

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Initial Phase II study results of ofatumumab in patients with RRMS announced

Study finds additional targets for new therapies to treat advanced prostate cancer patients

VA addresses health concerns including possible HIV exposure and Veterans' general poor health

Aspire Capital Fund to purchase Bionovo shares of common stock worth $15.0 million

Hologic enters definitive agreement to acquire Sentinelle Medical

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena Cava Filter

International conference focuses on HPV's impact on women

PI3 kinase boosts body heat, helps burn excess calories

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

CPRIT grants RBM $3 million Company Commercialization Award to expand OncologyMAP program

Amorfix partners with reMYND to offer A4 amyloid testing services

Elsevier, SIOG launch Journal of Geriatric Oncology

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

Hope for ovarian cancer patients not responding to conventional chemotherapy

CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL

Novel molecular pathway that regulates invasive growth, metastasis in ER-positive breast cancer discovered

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in